MENU
+Compare
SLS
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$1.09
Change
+$0.01 (+0.92%)
Capitalization
99.02M

SLS SELLAS Life Sciences Group Forecast, Technical & Fundamental Analysis

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications... Show more

Industry: #Biotechnology
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SLS with price predictions
Apr 01, 2025

SLS sees MACD Histogram crosses below signal line

SLS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on March 28, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

SLS moved below its 50-day moving average on March 26, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SLS crossed bearishly below the 50-day moving average on March 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SLS entered a downward trend on March 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on April 01, 2025. You may want to consider a long position or call options on SLS as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for SLS moved above the 200-day moving average on March 20, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

SLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.460) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (251.391).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SLS is expected to report earnings to rise 75.00% to -10 cents per share on May 08

SELLAS Life Sciences Group SLS Stock Earnings Reports
Q1'25
Est.
$-0.10
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.04
Q1'24
Beat
by $0.02
The last earnings report on March 20 showed earnings per share of -5 cents, beating the estimate of -10 cents. With 720.75K shares outstanding, the current market capitalization sits at 99.02M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
7 Times Square
Phone
+1 646 200-5278
Employees
16
Web
https://www.sellaslifesciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AOIFF1.450.02
+1.40%
Africa Oil Corp.
IBDSF16.340.22
+1.36%
Iberdrola S.A.
CUTRQ0.01N/A
N/A
Cutera Inc
SDVKY21.12-0.02
-0.09%
Sandvik AB
ALSMY2.13-0.03
-1.39%
Alstom

SLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SLS has been loosely correlated with FULC. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLS jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLS
1D Price
Change %
SLS100%
+0.93%
FULC - SLS
48%
Loosely correlated
-4.17%
NKTR - SLS
42%
Loosely correlated
-6.28%
AKRO - SLS
39%
Loosely correlated
-4.55%
SNPX - SLS
34%
Loosely correlated
+0.51%
AXON - SLS
32%
Poorly correlated
+2.90%
More